Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22837453 | 1.00 | HTR2A (0.47) | HTR2ADRD2DRD3HTR1ACHRM2 | |
| SCHEMBL17014302 | 0.83 | HTR1A (0.50) | DRD2DRD3HTR1ACHRM2CHRM1 | |
| SCHEMBL3586039 | 0.81 | MTNR1B (0.57) | MTNR1AMTNR1B | |
| SCHEMBL10321230 | 0.80 | DRD2 (0.46) | HTR2ADRD2DRD3HTR1AAADAT | |
| SCHEMBL10321232 | 0.80 | DRD2 (0.46) | HTR2ADRD2DRD3HTR1AAADAT | |
| SCHEMBL7543923 | 0.80 | HTR2A (0.47) | HTR2ADRD2DRD3HTR1ACHRM2 | |
| SCHEMBL17965649 | 0.79 | HTR2A (0.40) | HTR2ADRD2DRD3HTR1APOLL | |
| SCHEMBL22837450 | 0.78 | CETP (0.46) | HTR2ADRD2DRD3HTR1A | |
| SCHEMBL13352195 | 0.78 | CYP1A2 (0.47) | DRD2DRD3HTR1ACHRM2 | |
| SCHEMBL18034965 | 0.78 | SLC6A2 (0.43) | HTR2ADRD2DRD3HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018154519-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| US-20180244611-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| EP-0940386-B1 | Benzocyclobutan compounds, their process for preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-05-22 | — | — | EP | disclosed |
| US-6107345-A | ANTIDEPRESSANT; PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 2000-08-22 | — | — | US | disclosed |
| EP-0940386-A1 | Benzocyclobutan compounds, their process for preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244611-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | HTR2A 3843/4885DRD2 4611/4885DRD3 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.